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Abstract
Background: The inherited predisposition to development of specific histologic subtypes of 
invasive breast carcinoma has been incompletely investigated. Using a large, population-based 
database, we sought to investigate familial clustering of breast cancer by histologic subtype.
Methods: Using the Utah Population Database (UPDB), which links genealogy records to the 
state-wide National Cancer Institute Surveillance, Epidemiology, and End-Results cancer registry, 
we identified patients with breast cancer by histology and tested for evidence of shared genetic 
predisposition to histologic specific subtypes by examining pairwise relatedness and estimating 
relative risk (RR) among first-, second-, and third-degree relatives.
Results: We identified 23,629 individuals in the UPDB with at least 3 generations of genealogy 
and at least one primary breast cancer, 2883 (12.2%) of which were specific histologic subtypes 
other than invasive ductal carcinoma (including inflammatory [n=178], lobular [n=1688], and 
mucinous [n=542]). Statistically significant excess distant relatedness was identified for the 
mucinous subtype (p=0.011) as well as for inflammatory breast cancers (p=0.024). The RR for 
breast cancer of any histology in second-degree relatives was significantly increased for patients 
with inflammatory (RR 1.32 [1.02, 1.68]; p=0.03), lobular (RR 1.36 [1.25, 1.47]; p<0.001), and 
mucinous (RR 1.27 [1.12, 1.44]; p=0.00021) subtypes.
Conclusions: These findings provide evidence for significant familial clustering within 
histological subtypes for lobular, mucinous and inflammatory breast carcinomas. Further research 
is required to identify the underlying genetic variants responsible for the increased risk. Studies of 
high risk pedigrees segregating a specific histologic subtype could be a powerful design for 
predisposition gene identification.
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Using the Utah Population Data Base, we found evidence of histology-specific familial clustering 
for mucinous, lobular, and inflammatory breast carcinomas. Breast cancer cases with specific 
histologies appear to cluster more in pedigrees than expected, and the homogeneous pedigrees 
observed may be informative for identification of the predisposition genes responsible.
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Introduction
Breast cancer is a heterogeneous disease. According to the World Health Organization, 
breast cancer can be classified based on histopathologic characteristics including cell 
morphology, architecture, and growth patterns into 21 distinct subtypes.1, 2 While the 
majority of invasive breast cancers are ductal carcinomas, there are a number of more 
uncommon histologic subtypes that are associated with either a more aggressive or a more 
indolent disease course.
Pure mucinous and tubular breast cancers are examples of more indolent tumor subtypes. 
Mucinous tumors comprise 1–2% of breast cancers, and are typically hormone receptor 
positive and HER2 negative.3 They are frequently diagnosed at an older age and are 
associated with a better than average breast cancer-specific survival. In addition to being 
histologically distinct, mucinous cancers also differ genomically from more common breast 
cancer subtypes, including lower genomic instability and a lower frequency of mutations in 
genes in the PI3K pathway.3, 4
Inflammatory breast cancer, in contrast, is an aggressive type of breast cancer. It is not a 
specific histology per se, but rather is diagnosed based on characteristic clinical changes 
including rapid development of diffuse erythema and edema of the breast.5–8 About 2.5% of 
patients diagnosed with breast cancer have inflammatory breast cancer, and it is often at 
advanced stage at the time of diagnosis.6 Dermal lymphatic invasion can be noted on 
pathology, although this finding is not required for the diagnosis. Prior reports have shown 
an increased risk of inflammatory breast cancer in patients with younger age and higher 
body mass index.9
About 5–10% of breast cancers are inherited. Patients with mutations in specific genes, 
including BRCA1, BRCA2, TP53, and PTEN, have a high risk of developing breast cancer.
10
 More recently, it has become apparent that mutations in numerous additional genes, 
including CHEK2 and PALB2, are associated with a more moderate risk of breast cancer.11 
However, the only histologic subtypes that have been associated with mutations in specific 
genes are lobular carcinoma with CDH1, which encodes e-cadherin,12 and medullary 
carcinoma with BRCA1.13 Other histologies, including mucinous carcinoma, have not 
previously been found to be clearly associated with a family history of breast cancer. 
Recently, inflammatory breast cancer has been reported to be associated with a first-degree 
family history of breast cancer in some but not all studies; mutations in specific genes have 
not yet been identified.9, 14, 15
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The possibility of additional genetic contributions to breast cancer exists. Identification of 
excess familial clustering using the genealogical index of familiality (GIF) is a method that 
can be used to provide evidence that risk of a disease is mediated by inherited genetic 
factors. The GIF has previously been described in studies evaluating the familiality of 
cancer.16–19 Determining whether a disease exhibits familial clustering can be used to 
calculate disease risk in relatives, to increase the understanding of the disease pathogenesis, 
and ultimately can permit identification of underlying causative mutations. In the context of 
the excess familial clustering that is generally recognized for breast cancers of any histology, 
we used this established methodology to investigate hypotheses of additional genetic 
contributions to predisposition to specific breast cancer histologic subtypes and 
inflammatory breast cancer using a large population-based database.
Materials and methods
Utah Population Database
A unique Utah resource consisting of the genealogy of the Utah Northern European founders 
from the mid 1800s and their descendants to modern day linked to a statewide National 
Cancer Institute Surveillance, Epidemiology, and End-Results (SEER) Cancer Registry from 
1973 was used to describe the familial clustering of breast cancer cases by histologic 
subtypes and of inflammatory breast cancer. This resource, the Utah Population DataBase 
(UPDB),20, 21 includes data on over 11 million individuals. The approximately 3 million of 
these individuals who have at least 3, and up to 16, generations of genealogy data connecting 
to Utah founders were analyzed here. The Utah Cancer Registry was established statewide in 
1966 and became one of the original SEER Registries in 1973. All independent primary 
cancers diagnosed or treated in Utah are recorded. Study approval was obtained from the 
University of Utah Institutional Review Board and the Utah Resource for Genetic and 
Epidemiology Research Review Board. Statistical analyses were performed using tools 
created specifically for the UPDB.
Breast Cancer Cases
Approximately 150,000 of the 3 million individuals with genealogy in UPDB have a linked 
Utah Cancer Registry record; 23,629 of these linked cancer records are for individuals 
diagnosed with breast cancer, and 155 of these breast cancers occurred in males. Breast 
cancer cases were identified using the International Classification of Diseases for Oncology 
(ICD-Oncology) Revision 3 definition of the primary site 500–509 and including histology 
codes 8000 to 9589 (leukemias and lymphomas excluded). In particular, this classification 
was used to assign specific histologic subtypes as follows: angiosarcoma (9120); apocrine 
(8401); inflammatory (8530); lobular (8520); medullary (8510, 8512, 8513); metaplastic 
(8570–8572, 8575); mucinous (8480); phyllodes (9020); and tubular (8211).
Genealogical Index of Familiality Method
The genealogical index of familiality (GIF) method was developed for use with the UPDB 
and allows a test of the hypothesis of excess relatedness among individuals with a phenotype 
of interest. The GIF compares the average pairwise relatedness of a set of individuals (e.g. 
all breast cancer cases) to the expected pairwise relatedness for a similar set of individuals in 
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the UPDB. The coefficient of kinship is used to measure relatedness,22 and pairs can be 
defined based on their genetic distance. The expected pairwise relatedness for a group of 
individuals is estimated in a set of randomly selected matched controls. Randomly selected 
controls from the UPDB were matched to cases by sex, 5-year birth year cohort, and birth 
place (Utah or not Utah). For each GIF test of a set of cases, the expected pairwise 
relatedness was estimated as the average pairwise relatedness computed for 1,000 sets of 
matched controls. The significance of the case GIF was assessed empirically by its position 
within the 1,000 control GIF statistic values. Breast cancer histologic subsets with sample 
sizes less than 100 were not analyzed with the GIF method.
The GIF method tests for excess relatedness or familiality, but does not distinguish between 
relatedness due to genetics versus common environment. The distant GIF (dGIF) test was 
therefore created as an extension of the GIF statistic; it is performed while ignoring all 
relationships closer than third-degree, to test for an excess of distant relationships, which is 
unlikely in the absence of a heritable contribution.
Estimation of Relative Risk in Relatives
Evidence for a familial or genetic contribution to disease is commonly considered using 
estimates of relative risk in relatives. Published risks for cancer in relatives are typically 
limited to close relationships (first-degree). Relative risks (RR) for breast cancer were 
estimated in both close and distant relatives in the UPDB utilizing birth- and sex-specific 
cohort rates of breast cancer estimated internally from the UPDB as follows.
All individuals in the UPDB genealogy with at least 3 generations of genealogy were 
assigned membership to a birth year- (5-year groups), sex-, and birthplace-specific (Utah or 
not Utah) cohort. Internal, cohort-specific rates of breast cancer (and histologic subtypes) 
were calculated for all cohorts separately, by summing the number of individuals with the 
selected breast cancer histology in each cohort, and dividing by the total number of 
individuals in the cohort. Expected numbers of cancer cases for a set of individuals (e.g. 
first-degree relatives of mucinous breast cancer cases) were estimated by counting all first-
degree relatives of the set of mucinous breast cancer cases by cohort, multiplying the 
number of relatives per cohort by the cohort-specific cancer rate, and then summing over all 
cohorts. The observed numbers of cancer cases were counted, without duplication, in the set 
of relatives being considered. RR = (observed number of cases)/(expected number of cases) 
is an unbiased estimator of RR. Exact two-sided Poisson probabilities were calculated under 
the null hypothesis that the RR = 1.0, and 95% confidence intervals were calculated based 
on the assumption that the number of observed cases follows a Poisson distribution, with 
mean equal to the expected number of cancers.
High-risk Pedigrees
Given a set of individuals selected from the UPDB, all related clusters of these individuals 
who descend from a common ancestor can be identified. All such clusters, or pedigrees, 
were identified for each subset of breast cancer cases with a specific histology; pedigrees 
were never completely overlapping, but cases could appear in more than 1 pedigree. To 
determine whether a pedigree is high-risk, the observed number of cases among the 
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descendants is compared to the expected number of cases. The expected number of, for 
example, breast cancer cases with mucinous histology, among the descendants of a set of 
pedigree founders is calculated by counting all descendants by cohort, multiplying the 
number of descendants in each cohort by the cohort-specific rate of mucinous type breast 
cancer (estimated as described above), and summing over all cohorts. An excess of observed 
to expected affected descendants of p<0.05 was used to classify a descending pedigree as 
high-risk for a specific subtype.
Results
We identified 23,629 individuals with at least 3 generations of genealogy connecting to Utah 
founders who had at least one primary breast cancer recorded in the Utah Cancer Registry. 
The majority of these cases were ductal histology or mammary carcinoma not otherwise 
specified; 53 apocrine carcinomas, 178 inflammatory breast cancers, 1688 lobular 
carcinomas, 542 mucinous carcinomas, 134 tubular carcinomas, 38 metaplastic carcinomas, 
32 phyllodes tumors, 341 medullary carcinomas, and 12 angiosarcomas were also identified.
Since inflammatory breast cancer does not represent a specific histology but rather is a 
clinical diagnosis, the clinical and pathologic characteristics can be heterogeneous. In this 
analysis, the cohort of 178 patients with inflammatory breast cancers had median age 58 and 
median survival of 31 months (Supplemental Table 1). Just over half of cancers were poorly 
differentiated. Almost 15% had metastatic disease at the time of diagnosis. In contrast, the 
invasive lobular and mucinous cancers were diagnosed in women at an older age, at an 
earlier stage, with a lower grade, and had a longer overall survival.
Genealogical Index of Familiality
Table 1 shows the results of the GIF test for excess relatedness for all breast cancers and for 
the 5 histologic subtypes with at least 100 cases observed. Shown for each subtype is the 
number of cases (N), the average pairwise relatedness (Case GIF), the mean GIF statistic for 
the 1,000 sets of matched controls (Mean Control GIF), the empirical significance for the 
overall GIF test (GIF p value), the average pairwise relatedness ignoring first- and second-
degree relationships (Case dGIF), the mean dGIF statistic for the 1,000 sets of matched 
controls (Mean Control dGIF), and the empirical significance for the distant GIF test (dGIF 
p value).
Statistically significant excess relatedness was observed for all breast cancer cases 
(p<0.001), and for the lobular (p=0.007) and mucinous subtypes (p=0.003) (Table 1). When 
close relationships were ignored, the dGIF test identified significant excess distant 
relatedness for the mucinous subtype (p=0.011) as well as for inflammatory breast cancers 
(p=0.024), but not for all breast cancers considered together or for the other tumor subtypes.
Relative risks
RRs were estimated for first- (FDR; Table 2), second- (SDR; Table 3), and third-degree 
relatives (TDR; Table 4) for all breast cancers, and for each of the histologic subgroups. 
Each table shows the subgroup, number of relatives (# FDRs, # SDRs, # TDRs, 
respectively), observed number of breast cancer cases of the same histologic subgroup 
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(Obs), expected number of breast cancer cases of the same histologic subgroup (Exp), 
significance of the test of RR = 1.0 (p value), and estimated relative risk and 95% confidence 
interval (RR [CI]); the observed and expected numbers of cases and the significance and RR 
with CI for breast cancer of any histologic type are also shown for each histologic subgroup.
FDRs with the same histologic type as the proband were only observed for the 2 largest sets 
of probands, lobular and mucinous histologies, and significantly increased RR was observed 
for each (Table 2). The RR for breast cancer of any histology in FDRs was significantly 
increased for patients with all examined histologic subtypes; and was increased, but not 
significantly, for 2 of the smallest subgroups, phyllodes and metaplastic tumors.
Similarly for SDRs, affected relatives were only observed for the 2 largest subgroups, 
lobular and mucinous; significantly increased risk in second degree relatives was only 
observed for the lobular subgroup (RR = 1.56, p=0.003) (Table 3). The RR for breast cancer 
of any histology in SDRs was significantly increased for patients with inflammatory (RR 
1.32 [1.02, 1.68]; p=0.03), lobular (RR 1.36 [1.25, 1.47]; p=<0.001), and mucinous (RR 
1.27 [1.12, 1.44]; p=0.00021) subtypes.
For TDRs, significantly elevated risk for breast cancer of the same tumor subtype was 
observed for lobular (RR 1.35 [1.12, 1.62], p=0.001) and mucinous (RR 1.84 [1.16, 2.76]; 
p=0.007) cancers (Table 4). The RR for breast cancer of any histology in TDRs was 
significantly elevated for patients with lobular (RR 1.21 [1.15, 1.27]; p=<0.001), mucinous 
(RR 1.09 [1.02, 1.19]; p=0.04), medullary (RR 1.15 [1.02, 1.28]; p=0.02), and apocrine (RR 
1.36 [1.05, 1.74]; p=0.02) subtypes.
High-risk Pedigrees
Analysis of all relationships among breast cancer cases for the inflammatory and mucinous 
subtypes (the 2 subtypes with significant excess relatedness observed) identified 48 high risk 
inflammatory breast cancer pedigrees including between 2 and 4 inflammatory breast cancer 
cases, and 110 high-risk mucinous breast cancer pedigrees including between 2 and 13 
mucinous breast cancer cases. Figure 1 shows an example high-risk mucinous breast cancer 
pedigree. The top generation shows a male with 2 spouses. Of the total of over 10,630 
descendants of this male founder in UPDB, 5 have been diagnosed with mucinous breast 
cancer (0.8 expected; p = 0.0018). Overall there are 65 breast cancer cases among the 
descendants with 43.9 expected (p=0.0017); the other breast cancers observed include 2 
inflammatory, 2 lobular and 1 medullary breast cancer. Analysis of all relationships among 
lobular breast cancer cases (the subtype with significant excess risks for first-, second-, and 
third-degree relatives) identified 273 high-risk lobular breast cancer pedigrees including 
between 2 and 14 related lobular breast cancer cases.
Discussion
Using a unique population-based resource linking decades of statewide cancer data to over 
150 years of genealogy data, the hypothesis of histology-specific clustering of breast cancer 
cases has been investigated. Previously published findings from this resource provided 
evidence for clustering of lobular breast cancers and these results have been confirmed here.
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16
 In addition, evidence was observed for significant familial clustering for mucinous and 
inflammatory breast carcinomas. No significant evidence for increased relatedness or risk 
for the same histologic subtype of breast cancer was observed for the other breast cancer 
histologies considered; however small sample sizes for many of these uncommon subgroups 
limited power to identify clustering. Most histological subtypes were associated with 
increased RR for breast cancer of any histologic type in first-, second-, and third-degree 
relatives, which is unsurprising given that it is well recognized that a diagnosis of breast 
cancer is associated with increased risk to relatives.
The GIF analysis for excess familiality was limited to the larger histologic subgroups, and 
identified significant excess relatedness for distant relationships for both inflammatory and 
mucinous subgroups, providing strong evidence for a heritable, rather than just a shared 
environment, contribution for these specific types of breast cancer. The RR analysis 
considered even the smaller histologic subgroups, but limited numbers of affected relatives 
with breast cancer of the same histology were observed. Nevertheless, a significantly 
increased risk for lobular breast cancers in the first-, second-, and third-degree relatives of 
lobular cancer cases was observed, again providing strong evidence for a heritable 
contribution to predisposition. Elevated risk for mucinous breast cancer was also observed in 
first-, second-, and third-degree relatives, and the elevation was statistically significant in the 
first-, and third-degree relatives. These findings suggest genetic contribution to risk, 
although additional environmental contribution to risk cannot be excluded.
In a nested case control study from the Breast Cancer Surveillance Consortium that included 
617 inflammatory breast cancer cases, first-degree family history of breast cancer was 
associated with increased risk of inflammatory breast cancer.9 The multivariable rate ratio 
was 1.52 (95% CI 1.15, 2.01). In a second study, patients with inflammatory breast cancer 
had a higher likelihood of family history of breast cancer compared to unaffected controls, 
although a lower likelihood compared to patients with non-inflammatory breast cancer.14 
Interestingly, in the latter cohort they identified several inflammatory breast cancer patients 
with multiple first- and second-degree family members with non-inflammatory breast 
cancer. Our findings both confirm and extend this finding, as we were able to examine 
relationships out to third-degree (first cousins) and identified a significant excess of distant 
relatedness. The RR for third-degree relatives for inflammatory breast cancer was elevated, 
but not significantly (RR=2.00; 95%CI 0.24, 7.21); sample sizes are small, but this indicates 
that the evidence for the significant excess relatedness observed in the dGIF test came from 
an excess of even more distant relationships.
It was somewhat surprising that we did not identify increased relatedness among patients 
with medullary carcinoma given its known association with tumors with pathogenic variants 
in BRCA1. However, according to the literature only 10–15% of BRCA1 mutated tumors 
have pure medullary histology.13 In addition, only about 11% of medullary tumors, 
regardless of family history, had identified pathogenic variants in BRCA1.23 Therefore, our 
results support prior findings that only a minority of medullary breast cancer cases are likely 
due to an inherited predisposition.
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Strengths of this analysis are the large number of primary cancers in the database, 
histopathological confirmation of all cases in the Utah Cancer Registry, and comprehensive 
genealogy information including large numbers of first-, second-, and third-degree relatives 
with known cancer status. The UPDB database includes genealogy from the mid-1800s and 
statewide cancer data from 1966; nevertheless, some breast cancer histologic subgroups 
were rarely observed, and significant conclusions for some hypotheses will require larger 
data sets. The total sample size for primary inflammatory breast cancers was limited, and no 
FDRs or SDRs diagnosed with inflammatory breast cancer were observed. However, it is 
possible that inflammatory breast cancer cases may be incompletely represented in the 
database since it is a clinical, rather than histologic, diagnosis, and cases without evidence of 
dermal lymphatic invasion in a pathology specimen may not have been identified.
Even among the histologic subgroups with small sample sizes some pedigrees including 
related breast cancer cases with the same histology were identified to have a significant 
excess of breast cancer. These rare pedigrees may provide a powerful resource to identify 
new breast cancer predisposition genes or to enhance our understanding of known 
predisposition genes.
The analysis has some limitations. Data for some individuals could have been censored due 
to diagnosis of cancer outside Utah or before 1966. Pathology reports and slides were not 
reviewed and some records date back decades. In addition, changes in histologic 
classification have occurred over time, and these updates or subclassifications may not be 
reflected in the available patient-level data. Although it would have been interesting to 
examine associations between familiality and both clinicopathologic characteristics and 
disease outcomes, especially for the inflammatory breast cancer cohort, unfortunately 
neither receptor status nor treatment information is available at this time.
Censoring also occurred for individuals who do not have genealogy data in the UPDB or 
who did not appropriately link to their genealogy data. Approximately 60% of Utah Cancer 
Registry records link to an individual with Utah genealogy data; females have lower record 
linking rates than males due to name changes. In addition, genealogy does not always 
represent biological relationships. These censorship issues can be assumed to occur 
uniformly across both cases and controls in UPDB and should not bias analyses, although 
they can lower power.
The Utah population represented in the UPDB largely consists of individuals of Northern 
European ancestry. The population has been shown to be genetically identical to other 
Northern European populations. The original Utah pioneers, who began arriving in Utah in 
1847, were largely unrelated; the Utah population continues to have low or normal 
inbreeding compared to the United States.24 In addition, the Utah population has a high 
proportion of women with higher average number of pregnancies, younger age at first 
childbirth, lower alcohol and tobacco use, and lower rates of post-menopausal obesity, all of 
which could impact the rates of breast cancer incidence. Therefore the results of this study 
are likely applicable to populations of females similar to the Utah population, but should not 
be extrapolated to other populations without validation.
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In summary, using genealogy data from a large population-based database, this study 
provides additional evidence supporting a genetic predisposition to inflammatory breast 
cancer as well as lobular and mucinous breast cancer histologies. While estimated RRs are 
modest, the important point is that breast cancer cases with specific histologies appear to 
cluster more in pedigrees than expected, and these homogeneous pedigrees may be 
informative for identification of the predisposition genes responsible. Subsequent 
identification of inherited genetic variants should be performed in order to identify potential 
etiologies of specific breast cancer subtypes.
Supplementary Material
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Figure 1. Example of a high-risk mucinous breast cancer pedigree from the Utah Population 
DataBase.
Females are designated by circles and males by squares. Individuals with mucinous breast 
cancer are designated by a solid symbol. Deceased individuals are shown with a hash-mark 
through the symbol.
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Table 1.
Genealogical Index of Familiality (GIF) Relatedness Analysis.
The number (N) of cases of all breast cancer and each subtype of breast cancer included in the analysis, the 
GIF for cases and controls and the p value for the comparison, as well as the distant GIF (dGIF) for cases and 
controls and the p value for the comparison, are provided.
Subtype N Case GIF Mean Control GIF GIF
P value
Case dGIF Mean Control dGIF dGIF
P value
Breast 23,629 2.93 2.72 <0.001 2.37 2.38 0.676
Inflammatory 178 3.54 2.68 0.147 3.54 2.36 0.024
Lobular 1688 3.07 2.72 0.007 2.36 2.40 0.619
Mucinous 542 3.65 2.71 0.003 2.88 2.34 0.011
Tubular 134 2.52 2.86 0.529 2.52 2.47 0.426
Medullary 341 2.12 2.69 0.897 2.12 2.33 0.723
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